TOUR THE FINAL EXHIBIT
PsA disease outcome measures
Explore different disease outcome measures…
…and their importance in defining PsA disease activity in clinical practice.
PsA=psoriatic arthritis.
LECTURE SERIES WITH DR. ALEXIS OGDIE
Gain insights about suboptimal disease outcomes and raising the standard of care for PsA
Watch the first video in a lecture series featuring Dr. Alexis Ogdie—distinguished professor, researcher, and clinician in rheumatology—and discover how consistently using clinical assessment measures and considering a patient’s daily activity goals, can lead to better PsA disease outcomes.
Many patients with PsA are not reaching optimal disease outcome goals in clinical practice1
~75% do not achieve minimal disease activity1*
*Based on MDA index;
MDA=minimal disease activity.
~80% do not achieve remission1*
*Based on cDAPSA remission
cDAPSA=Clinical Disease Activity Index for Psoriatic Arthritis.
Barriers to achieving optimal disease outcomes in PsA
The decision-making pathway for clinicians is complex, and there are multiple reasons why patients do not achieve optimal disease activity goals.2-5
Challenges in PsA disease management include:
- Disease heterogeneity2
- No definitive diagnostic tests3
- No consensus on preferred disease activity measures2
- Patient and clinician discordance on most important disease outcomes4,5
~40% of clinicians do not routinely use disease activity measures in clinical practice6
There is an opportunity to address this unmet need in the management of patients with PsA.6-8
How does the complexity of pathobiology affect the decision-making pathway?
Understanding the pathologic processes leading to axSpA is important to assessing and achieving improved disease outcomes.
NEXT ROOM IN THE OUTCOMES EXHIBIT
Setting higher goals
Explore how the implementation of stringent measures of axSpA disease activity is key to optimizing disease outcomes.
PREVIOUS EXHIBIT
PsA manifestations
Become a member of the RheuMuseum and be the first to know about new exhibits
- Smolen JS, Siebert S, Korotaeva TV, et al. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419-1428
- Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res. 2020;72(Suppl 10):82-109
- Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692
- Dures E, Hewlett S, Lord J, et al. Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. Patient. 2017;10(4):455-462
- Richette P, Tillett W, Ogdie A, et al. POS0309 Are patients’ and rheumatologists’ perceptions of the burden and treatment of psoriatic arthritis aligned? Results from the uplift survey. Ann Rheum Dis. 2022;81(Suppl 1):404-405
- Tillett W, McHugh N, Orbai AM, et al. Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership-recommended next steps. J Rheumatol Suppl. 2020;96:11-18
- Coates LC, FitzGerald O, Merola JF, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70(3):345-355
- Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479